Summit Creek Advisors LLC Makes New $3.42 Million Investment in Medpace Holdings, Inc. $MEDP

Summit Creek Advisors LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 6,449 shares of the company’s stock, valued at approximately $3,415,000.

A number of other large investors have also recently made changes to their positions in MEDP. BlackRock Inc. bought a new position in shares of Medpace in the second quarter worth about $1,323,047,000. AQR Capital Management LLC lifted its holdings in Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after buying an additional 324,293 shares in the last quarter. Wasatch Advisors LP boosted its position in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after buying an additional 116,354 shares during the period. Geode Capital Management LLC boosted its position in Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after buying an additional 24,625 shares during the period. Finally, Invesco Ltd. grew its stake in Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after acquiring an additional 85,517 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 17,610 shares of Medpace stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total value of $10,655,987.10. Following the completion of the transaction, the chief executive officer owned 615,802 shares in the company, valued at $372,627,948.22. This represents a 2.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 67,195 shares of company stock worth $37,989,998. 20.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Truist Financial raised their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and boosted their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Finally, BMO Capital Markets lifted their target price on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, Medpace has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace Price Performance

Shares of Medpace stock opened at $590.30 on Wednesday. The stock has a market cap of $16.48 billion, a price-to-earnings ratio of 34.60, a PEG ratio of 2.58 and a beta of 1.15. The firm’s 50-day moving average is $541.49 and its two-hundred day moving average is $491.49. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the business posted $3.10 EPS. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.